Blackford Announces Partnership with Us2.ai for Advanced Echo Interpretation
Blackford and Us2.ai today announced their partnership to bring advanced echocardiography analysis tools to the Blackford Platform. The Blackford Platform enables the seamless selection and integration of AI applications into medical imaging workflows, which supports the complex measurement and reporting needs of clinicians.
REDUCING TIME TO DIAGNOSIS
Heart disease remains the number one cause of death around the world. Echocardiography is an affordable, front-line tool used to diagnose and assess heart disease, but the process of acquiring, measuring, and analyzing the images is time-consuming. Groundbreaking machine learning technology from Us2.ai can reduce the time to process and interpret echocardiograms from 30 minutes to under 2 minutes, with zero variability and with accuracy comparable to expert clinicians.
“Cardiologists are under incredible time pressure, and we believe that harnessing the power of AI can enable more efficient and effective cardiac care,” said Ben Panter, Blackford Founder and CEO. “We’re excited to partner with Us2.ai and facilitate the availability of fast, reproducible echo analysis to global healthcare professionals via our whole-of-market AI platform.”
FULLY AUTOMATED CARDIAC MEASUREMENT AND REPORTING
After the echocardiographer acquires a study, the FDA and CE cleared Us2 software automatically analyzes all the heart chambers, using both 2D and Doppler views to create a full echo report with findings for heart structure and function. The fully automated cardiac measurements included in the software cover most standard measurements for adult transthoracic echocardiography recommended by the American and British Societies of Echocardiography and the European Association of Cardiovascular Imaging.
“This partnership accelerates our mission to automate the fight against heart disease,” said James Hare, CEO and co-founder of Us2.ai. “We are proud to partner with Blackford and take advantage of our growing list of global regulatory clearances to ensure cardiologists are armed with all the facts to detect heart issues early and with ease.’